CY1106259T1 - Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο - Google Patents
Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιοInfo
- Publication number
- CY1106259T1 CY1106259T1 CY20061101619T CY061101619T CY1106259T1 CY 1106259 T1 CY1106259 T1 CY 1106259T1 CY 20061101619 T CY20061101619 T CY 20061101619T CY 061101619 T CY061101619 T CY 061101619T CY 1106259 T1 CY1106259 T1 CY 1106259T1
- Authority
- CY
- Cyprus
- Prior art keywords
- taxane
- class
- warm
- human
- producing
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 229940123237 Taxane Drugs 0.000 abstract 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 5
- 241001465754 Metazoa Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο για την παραγωγή ενός αντιαγγειογόνου αποτελέσματος και/ή τη μείωση της αγγειακής διαπερατότητας σ' ένα θερμόαιμο ζώο όπως ο άνθρωπος, ιδιαίτερα σε μία μέθοδο για την αντιμετώπιση ενός καρκίνου που συμπεριλαμβάνει ένα συμπαγή όγκο, η οποία περιλαμβάνει τη χορήγηση ZD6474 σε συνδυασμό μ' ένα ταξάνιο• σε μία φαρμακευτική σύνθεση που περιέχει ZD6474 κι ένα ταξάνιο• σ' ένα συνδυασμένο προϊόν που περιέχει ZD6474 κι ένα ταξάνιο για χρήση σε μία μέθοδο θεραπευτικής αγωγής σε σώμα ανθρώπου ή ζώου• σ' ένα κιτ που περιλαμβάνει ZD6474 κι ένα ταξάνιο˙ στη χρήση του ZD6474 κι ενός ταξανίου στην παρασκευή ενός φαρμάκου για χρήση στην παραγωγή ενός αντιαγγειογόνου αποτελέσματος και/ή τη μείωση της αγγειακής διαπερατότητας σ' ένα θερμόαιμο ζώο όπως ο άνθρωπος που προαιρετικά μπορεί να υποβάλλεται σε ιονίζουσα ακτινοβολία.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126879.6A GB0126879D0 (en) | 2001-11-08 | 2001-11-08 | Combination therapy |
PCT/GB2002/005021 WO2003039551A1 (en) | 2001-11-08 | 2002-11-06 | Combination therapy comprising zd6474 and a taxane |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106259T1 true CY1106259T1 (el) | 2011-06-08 |
Family
ID=9925430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101619T CY1106259T1 (el) | 2001-11-08 | 2006-11-09 | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050043395A1 (el) |
EP (1) | EP1446124B1 (el) |
JP (1) | JP4694127B2 (el) |
KR (1) | KR100959607B1 (el) |
CN (1) | CN1298328C (el) |
AR (1) | AR037346A1 (el) |
AT (1) | ATE335488T1 (el) |
AU (1) | AU2002337382B2 (el) |
BR (1) | BR0213906A (el) |
CA (1) | CA2464758C (el) |
CY (1) | CY1106259T1 (el) |
DE (1) | DE60213845T2 (el) |
DK (1) | DK1446124T3 (el) |
ES (1) | ES2269769T3 (el) |
GB (1) | GB0126879D0 (el) |
HK (1) | HK1068546A1 (el) |
IL (2) | IL161744A0 (el) |
MX (1) | MXPA04004355A (el) |
NO (1) | NO328048B1 (el) |
NZ (1) | NZ532525A (el) |
PT (1) | PT1446124E (el) |
WO (1) | WO2003039551A1 (el) |
ZA (1) | ZA200403455B (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Vegf 억제제로서의 퀴나졸린 유도체 |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
DE60121931T2 (de) * | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
BR0307151A (pt) | 2002-02-01 | 2004-12-07 | Astrazeneca Ab | Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
SI1562955T1 (sl) | 2002-11-04 | 2008-06-30 | Astrazeneca Ab | Derivati kinazolina kot inhibitorji Src-triozin kinaze |
US20060142316A1 (en) * | 2003-02-13 | 2006-06-29 | Wedge Stephen R | Combination therapy |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
DE602004028834D1 (de) * | 2003-07-10 | 2010-10-07 | Astrazeneca Ab | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
EP1765313A2 (en) * | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
JP2008514577A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Zd6474及びイマチニブを含んでなる組合せ |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
AU2006328189B2 (en) * | 2005-12-22 | 2010-01-21 | Astrazeneca Ab | Combination of ZD6474 and pemetrexed |
CA2652926A1 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
CN101553253A (zh) * | 2006-09-29 | 2009-10-07 | 阿斯利康(瑞典)有限公司 | 用于癌症治疗的zd6474和贝伐单抗的组合 |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
ES2444128T3 (es) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
WO2010061208A2 (en) * | 2008-11-03 | 2010-06-03 | Astrazeneca Ab | Therapeutic treatment 555 |
CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
CN106478598B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种凡德他尼水合物晶体及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
DE69722793T2 (de) * | 1996-04-26 | 2004-05-19 | Genaera Corp. | Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9727524D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
CA2362937C (en) * | 1999-02-24 | 2011-03-22 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
ES2223705T3 (es) * | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
KR100881105B1 (ko) * | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Vegf 억제제로서의 퀴나졸린 유도체 |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
AU2003249000B2 (en) * | 2002-08-09 | 2007-04-05 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
US20060142316A1 (en) * | 2003-02-13 | 2006-06-29 | Wedge Stephen R | Combination therapy |
DE602004028834D1 (de) * | 2003-07-10 | 2010-10-07 | Astrazeneca Ab | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
JP2008514577A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Zd6474及びイマチニブを含んでなる組合せ |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
AU2006328189B2 (en) * | 2005-12-22 | 2010-01-21 | Astrazeneca Ab | Combination of ZD6474 and pemetrexed |
CN101553253A (zh) * | 2006-09-29 | 2009-10-07 | 阿斯利康(瑞典)有限公司 | 用于癌症治疗的zd6474和贝伐单抗的组合 |
-
2001
- 2001-11-08 GB GBGB0126879.6A patent/GB0126879D0/en not_active Ceased
-
2002
- 2002-11-06 WO PCT/GB2002/005021 patent/WO2003039551A1/en active IP Right Grant
- 2002-11-06 DK DK02772624T patent/DK1446124T3/da active
- 2002-11-06 EP EP02772624A patent/EP1446124B1/en not_active Expired - Lifetime
- 2002-11-06 MX MXPA04004355A patent/MXPA04004355A/es active IP Right Grant
- 2002-11-06 ES ES02772624T patent/ES2269769T3/es not_active Expired - Lifetime
- 2002-11-06 DE DE60213845T patent/DE60213845T2/de not_active Expired - Lifetime
- 2002-11-06 BR BR0213906-5A patent/BR0213906A/pt not_active IP Right Cessation
- 2002-11-06 NZ NZ532525A patent/NZ532525A/en not_active IP Right Cessation
- 2002-11-06 AU AU2002337382A patent/AU2002337382B2/en not_active Ceased
- 2002-11-06 AT AT02772624T patent/ATE335488T1/de active
- 2002-11-06 IL IL16174402A patent/IL161744A0/xx unknown
- 2002-11-06 JP JP2003541842A patent/JP4694127B2/ja not_active Expired - Fee Related
- 2002-11-06 CA CA2464758A patent/CA2464758C/en not_active Expired - Fee Related
- 2002-11-06 PT PT02772624T patent/PT1446124E/pt unknown
- 2002-11-06 KR KR1020047007020A patent/KR100959607B1/ko not_active IP Right Cessation
- 2002-11-06 CN CNB028267958A patent/CN1298328C/zh not_active Expired - Fee Related
- 2002-11-06 US US10/494,704 patent/US20050043395A1/en not_active Abandoned
- 2002-11-08 AR ARP020104292A patent/AR037346A1/es not_active Application Discontinuation
-
2004
- 2004-05-03 IL IL161744A patent/IL161744A/en not_active IP Right Cessation
- 2004-05-06 ZA ZA200403455A patent/ZA200403455B/en unknown
- 2004-06-07 NO NO20042365A patent/NO328048B1/no not_active IP Right Cessation
-
2005
- 2005-02-03 HK HK05100883A patent/HK1068546A1/xx not_active IP Right Cessation
-
2006
- 2006-11-09 CY CY20061101619T patent/CY1106259T1/el unknown
-
2011
- 2011-11-07 US US13/290,730 patent/US20120252827A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1298328C (zh) | 2007-02-07 |
NZ532525A (en) | 2006-11-30 |
DE60213845T2 (de) | 2007-03-29 |
AR037346A1 (es) | 2004-11-03 |
JP4694127B2 (ja) | 2011-06-08 |
DK1446124T3 (da) | 2006-11-13 |
KR20050043779A (ko) | 2005-05-11 |
KR100959607B1 (ko) | 2010-05-27 |
ATE335488T1 (de) | 2006-09-15 |
US20120252827A1 (en) | 2012-10-04 |
US20050043395A1 (en) | 2005-02-24 |
MXPA04004355A (es) | 2004-08-11 |
EP1446124A1 (en) | 2004-08-18 |
GB0126879D0 (en) | 2002-01-02 |
CN1612738A (zh) | 2005-05-04 |
IL161744A0 (en) | 2005-11-20 |
AU2002337382B2 (en) | 2008-06-12 |
IL161744A (en) | 2012-01-31 |
DE60213845D1 (de) | 2006-09-21 |
NO328048B1 (no) | 2009-11-16 |
PT1446124E (pt) | 2006-12-29 |
ZA200403455B (en) | 2005-08-29 |
NO20042365L (no) | 2004-06-07 |
HK1068546A1 (en) | 2005-04-29 |
ES2269769T3 (es) | 2007-04-01 |
CA2464758C (en) | 2010-09-28 |
WO2003039551A1 (en) | 2003-05-15 |
JP2005511597A (ja) | 2005-04-28 |
EP1446124B1 (en) | 2006-08-09 |
BR0213906A (pt) | 2004-08-31 |
CA2464758A1 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106259T1 (el) | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο | |
CY1106601T1 (el) | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
NO20064755L (no) | Kombinasjonsterapi | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20064753L (no) | Kombinasjonsterapi | |
NO20064754L (no) | Kombinasjonsterapi | |
DE60308403D1 (de) | Kombinationstherapie mit gemzitabin und zd6126 |